Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have the most potential upside if approved
EXTON, Pa., September 27, 2018 (Newswire.com) – To better understand what real-world moderate and severe atopic dermatitis patients look like in terms of disease burden, physician touchpoints, comorbidities and treatment journeys, Spherix Global Insights collaborated with 132 U.S. dermatologists and 65 allergists to analyze the records of 1,002 atopic dermatitis patients currently prescribed at least one pharmacologic agent for their disease. While the audit captured a host of clinical and non-clinical metrics on each patient, a large focus of this study was on current treatment with Dupixent and candidacy for biologic or small molecule treatment. Further analysis tied patient-level treatment patterns to the managing physicians and revealed significantly different practice patterns between dermatologists and allergists.
The study revealed that participating dermatologists tend to be more biologic/small molecule “friendly” than their allergist counterparts, with allergists significantly more likely to agree that they will exhaust all topical and traditional atopic dermatitis treatments before moving to a biologic or small molecule. Furthermore, dermatologists identified significantly more of their adult atopic dermatitis patients as currently treated with Dupixent or a candidate for biologic/small molecule treatment than allergists.
Real-world patient audit data on the level of Dupixent use in this population closely mirrors physician-reported estimates, and satisfaction with patients’ response is generally very high. Furthermore, patients treated with the first-in-class biologic have shown significant improvement in their atopic dermatitis symptoms over baseline referral reports. However, the agent is not a cure-all for every patient; the audit also captured charts for those currently not having an optimal response to Dupixent, patients previously treated with Dupixent that have since discontinued and patients who are considered good candidates for biologic/small molecule therapy but are currently not prescribed Sanofi/Regeneron’s agent. Reasons for non-treatment among eligible patients vary, but insurance and out-of-pocket cost concerns play a leading role in current non-treatment and are also at the source of a sizable number of captured Dupixent discontinuations.
Data on candidacy for agents in development was also collected, revealing that the JAK inhibitors have the most potential upside if approved. Audited patients are considered significantly more appropriate for treatment with one of the pipeline JAKs – ruxolitinib, PF-04965842, and upadacitinib – compared to any other late-stage agent, including Vanda Pharmaceutical’s tradipitant, Galderma’s nemolizumab, LEO pharma’s tralokinumab, AnaptysBIO’s ANB-020 and Amgen/AstraZeneca’s tezepelumab. Familiarity and future intent regarding the atopic dermatitis pipeline, as well as trending of the Dupixent launch, and overall current market dynamics are further explored in Spherix’s quarterly publication, RealTime Dynamix™: Atopic Dermatitis US.
About RealWorld Dynamix™
RealWorld Dynamix™: Moderate-to-Severe Atopic Dermatitis (US) is a large-scale patient audit of recently seen moderate-to-severe atopic dermatitis patients. To qualify, patients must be adults, seen within the past three months, currently pharmacologically treated (specifically for their AD) and classified as having moderate-to-severe disease. Spherix recruited 132 U.S. dermatologists and 65 U.S. allergists/immunologists to provide 1,002 patient records. Data collected includes clinical and non-clinical demographics, robust patient histories, current and past treatment regimens, referral patterns, co-morbidities, quality-of-life metrics, office visits and touchpoints, candidacy for biologic therapy, physician feedback about therapy satisfaction (specifically if currently treated with Dupixent or Eucrisa) and candidacy for pipeline agents.
About Spherix Global Insights
Spherix Global Insights is an independent business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:
Lynn Price, Immunology Franchise Head
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
To view media coverage of this release, click here.
